

Special Issue

Colorectal Cancer: New Diagnostic and Therapeutic Approaches

Message from the Guest Editors

This Special Issue, "Colorectal cancer: new diagnostic and therapeutic approaches", will mainly focus on novel and promising tools for the management of colorectal cancer (CRC). Nowadays, research is moving towards the detection of accurate and personalized biomarkers with high specificity and sensitivity in patients with CRC, by means of the so-called "liquid biopsy". Liquid biopsies have been proven to improve CRC screening and diagnosis, predict relapse and metastasis, assessing minimal residual disease and resistance to chemotherapy. Furthermore, gut microbiota showed potential utility in the diagnosis and treatment of CRC. The host–microbe interplay in CRC and the promotion of homeostatic immune response using microbe-targeted therapies could be helpful in preventing and/or treating CRC development. There is an essential need for new therapeutic approaches in patients with CRC, such as the development of more active and tolerable chemotherapy regimens that could help us overcome some of the therapeutic challenges of CRC.

Guest Editors

Prof. Dr. Antonio Biondi

Department of General Surgery and Surgical–Medical Specialties,
University of Catania, Catania, Italy

Dr. Marco Vacante

Unit of Internal Medicine Critical Area–ARNAS Garibaldi, Catania, Italy

Deadline for manuscript submissions

closed (30 November 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/71752

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).